Novo Nordisk, tje manufacturer behind Ozempic and Wegovy has another weight loss medication in the works — but according to ...

The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.

Key Takeaways Novo Nordisk's U.S.-listed shares lost ground Friday after a Phase 2a trial of the pharmaceutical firm’s latest ...

Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental ...

Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral ...

The company noted that Wegovy is the first obesity medication to receive a positive opinion recommending a label update that reflects reduced symptoms and improved physical limitations and exercise ...

Shares of Novo Nordisk (NYSE:NVO) fell on Wednesday after Bloomberg reported that Ozempic, Novo Nordisk’s diabetes drug, is ...

Health-care companies fell amid fears of pharmaceutical drug-price controls. Novo Nordisk's Ozempic is "very likely" to be one the next drugs to have its price slashed in bargaining with the U.S.

--"It is very likely that Ozempic will be part of negotiations in the coming round, and we're ready for that," Ulrich Otte, senior vice president of finance & operations for Novo Nordisk, said Tuesday ...

Novo Nordisk expects to repurchase B shares for an amount up to DKK 20 billion during a 12-month period beginning 6 February 2024. As of 13 September 2024, Novo Nordisk has since 6 February 2024 ...

Partnership leverages Korro’s proprietary OPERATM platform to enable its oligonucleotide-directed RNA edits into two undisclosed targets; ...